C
Cornelis Kluft
Researcher at University of Southern Denmark
Publications - 246
Citations - 8571
Cornelis Kluft is an academic researcher from University of Southern Denmark. The author has contributed to research in topics: Plasminogen activator & Fibrinolysis. The author has an hindex of 46, co-authored 245 publications receiving 8140 citations. Previous affiliations of Cornelis Kluft include Leiden University & Netherlands Organisation for Applied Scientific Research.
Papers
More filters
Journal ArticleDOI
Effects of moderate alcohol consumption on platelet function, tissue-type plasminogen activator and plasminogen activator inhibitor
TL;DR: The effects of alcohol on t-PA and PAI activity appeared mainly in the older age group, whereas the t- PA activity in this group was already much lower, irrespective of alcohol consumption.
Journal ArticleDOI
Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
Geert-Jan Brouwers,Frank W.G. Leebeek,Michael W.T. Tanck,J. Wouter Jukema,Cornelis Kluft,Moniek P.M. de Maat +5 more
TL;DR: The role of plasma TAFI antigen (Ag) levels and gene polymorphisms in arterial thrombosis is still not elucidated in this article, however, the association between plasma tAFI Ag levels and the tPA mediated plasminogen activation was determined.
Journal ArticleDOI
On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma.
TL;DR: An enzyme immuno assay was developed to measure complexes of tissue-type plasminogen activator (t-PA) with C1-inhibitor in order to study the role of C1 inhibitor as an inhibitor of t-PA in plasma.
Journal ArticleDOI
The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.
Marianne G. Pouwer,Marianne G. Pouwer,Elsbet J. Pieterman,Lars Verschuren,Martien P. M. Caspers,Cornelis Kluft,Ricardo Garcia,Jurjan Aman,J. Wouter Jukema,Hans M.G. Princen +9 more
TL;DR: While imatinib showed a beneficial cardiovascular risk profile, nilotinib and ponatinib increased the cardiovascular risk through induction of a pro-thrombotic state.
Journal ArticleDOI
Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects.
Pieter-Jan de Kam,Peter Grobara,Marita Prohn,Floris Höppener,Cornelis Kluft,Jacobus Burggraaf,Ronald B. Langdon,Pierre Peeters +7 more
TL;DR: Administration of sugammadex is associated with a dose-related, limited and transient prolongation of APTT and PT(INR) that is unlikely to be of clinical relevance.